Agios Pharm Correlations
AGIO Stock | USD 32.66 0.98 3.09% |
The current 90-days correlation between Agios Pharm and Day One Biopharmaceuticals is 0.24 (i.e., Modest diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Agios Pharm Correlation With Market
Average diversification
The correlation between Agios Pharm and DJI is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Agios Pharm and DJI in the same portfolio, assuming nothing else is changed.
Agios |
Moving together with Agios Stock
Moving against Agios Stock
0.51 | CMRX | Chimerix | PairCorr |
0.39 | PFE | Pfizer Inc | PairCorr |
0.38 | FNA | Paragon 28 | PairCorr |
0.37 | CPIX | Cumberland Pharmaceuticals | PairCorr |
0.54 | NYXH | Nyxoah | PairCorr |
0.49 | KIDS | Orthopediatrics Corp | PairCorr |
0.36 | LUCD | Lucid Diagnostics | PairCorr |
0.36 | NVRO | Nevro Corp Sell-off Trend | PairCorr |
0.39 | BRK-A | Berkshire Hathaway | PairCorr |
0.39 | BRK-B | Berkshire Hathaway | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Agios Stock performing well and Agios Pharm Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Agios Pharm's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
MREO | 2.60 | (0.49) | 0.00 | (0.72) | 0.00 | 6.16 | 20.77 | |||
BPMC | 2.13 | 0.06 | 0.00 | (0.02) | 0.00 | 5.39 | 26.30 | |||
DAWN | 2.87 | (0.56) | 0.00 | (0.68) | 0.00 | 6.36 | 22.86 | |||
BMRN | 1.17 | 0.13 | 0.11 | 1.91 | 1.60 | 3.04 | 8.07 | |||
IDYA | 2.36 | (0.55) | 0.00 | (1.44) | 0.00 | 4.11 | 12.18 | |||
ANAB | 4.27 | 0.37 | 0.07 | 0.19 | 4.44 | 9.84 | 43.41 | |||
MGTX | 3.13 | 0.43 | 0.14 | (1.43) | 3.47 | 5.56 | 34.28 | |||
KROS | 3.98 | (1.76) | 0.00 | (17.87) | 0.00 | 4.41 | 73.15 | |||
FIXX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
KYMR | 2.89 | (0.25) | 0.00 | (0.25) | 0.00 | 5.50 | 23.03 |
Agios Pharm Corporate Management
DSc FRSC | CoFounder Board | Profile | |
Dr DACVP | Consultant | Profile | |
Sarah MD | Chief Development | Profile | |
James Burns | Corporate Officer | Profile | |
Ellen LoPrestiv | Chief Officer | Profile | |
Clive Patience | Chief Officer | Profile | |
ShinSan Su | CoFounder Board | Profile |